Roche maps out innovation journey of personalized health care at the CIIE - (Shanghai Daily via NewsPoints Desk)

  • Roche is presenting an "innovation journey of personalised healthcare" at the second China International Import Expo (CIIE), reported the Shanghai Daily.

  • André Hoffmann, vice chairman of the board at Roche, said "China plays a vital role for Roche globally. With our strong pipeline...we are confident about our long-term growth prospects by bringing more innovative products in China to benefit more Chinese patients."

  • In the past year, Roche has been quickening the pace of launching several new products in China in a bid to enable more Chinese patients to get access to global advanced therapies at the earliest possible time, the news source said. 

  • It noted, for example, that the breast cancer drug Perjeta obtained approval for its second indication in China in August, just eight months after obtaining the first in December 2018.

  • Meanwhile, Roche's five targeted therapies have so far been included in the National Reimbursement Drug List (NRDL) in China. 

  • Roche is also actively working with regulators and partners to enable more innovative drugs to enter the NRDL so that more patients can afford these medications, the news source added.

To read more NewsPoints articles, click here.